{"ticker": {"uuid": "6964eb5f-72a7-4c0c-8cb4-18fe981664a1", "symbol": "ANRO", "name": "Alto Neuroscience, Inc.", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE", "summary": "Alto Neuroscience (NYSE: ANRO) has announced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, aiming to raise approximately $100 million in gross proceeds. The offering is managed by BofA Securities and Stifel, Nicolaus & Company", "url": "https://www.minichart.com.sg/2026/07/14/alto-neuroscience-announces-3-7-million-underwritten-offering-of-common-stock-on-nyse/", "source_name": "Minichart", "published_at": "2026-07-14T16:12:23", "published_display": "14 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $28", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPcHAwbUxnUEExVVV0TldiYU9MU1VwbTVDcldlSmI4R0ppYnVBMkZCQjdhVlViX25QT3RPUy1iOWh2dkt4TFJxaXp0REhJUDZhLTdLbzZyWUFsSkhlV05zV29qYy1adWh0X0MzOFJxd3d2R3FCUzFhWTBpeVhrMW9nbXpvNUlBMDJPbVZjRl9Yd2ZOMzB2VXRocXdlaVFLcnJLZ0JEQUVpS0RRR2VNRWF1VDZWMXI?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T11:34:21+00:00", "published_display": "14 Jul 2026 11:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE: ANRO) sells 3,776,436 shares at $26.48", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNU3hZdUhJM0x0SENzODgwVmV2WUlnT3F0YWR0ek9KNDJpRGlMSkhFM1NydmotUWZMNkdyM0dKaS1LVVhWUE9tcjV3MWhwM2w1eFpXOVpPV2lOdEdSMk1VUzR4Q2dneUVRZ3luQnZvdkZDOEdOV1hxRl9NampFMVFhOEJpQS1lNUZScGFvMTdaRG9YR2lGT3ZnYUpNV2ttYy10YnFEOUJYa20tbGUtU3kwZWpRLVp0X05CMUp1NTZtckdrYW5Tdnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T10:38:21+00:00", "published_display": "14 Jul 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale", "summary": "Alto Neuroscience (NYSE: ANRO) announced it will raise approximately $93.9 million through an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share. The company plans to use these net proceeds, along with existing cash, to expand the clin", "url": "https://www.stocktitan.net/sec-filings/ANRO/8-k-alto-neuroscience-inc-reports-material-event-956e138c0ce0.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:13:25", "published_display": "14 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham Advises on Alto Neuroscience\u2019s US$100 Million Underwritten Registered Direct Offering of Common Stock", "summary": "Latham & Watkins LLP is advising the underwriters for Alto Neuroscience, Inc.'s underwritten registered direct offering of 3,776,436 shares of common stock. The offering is priced at US$26.48 per share, expecting to generate approximately US$100 million in gross proceeds. The dea", "url": "https://www.lw.com/en/news/2026/07/latham-advises-on-alto-neuroscience-underwritten-registered-direct-offering-of-common-stock", "source_name": "Latham & Watkins LLP", "published_at": "2026-07-13T17:09:54", "published_display": "13 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alto Neuroscience (NYSE: ANRO) estimates $244.2M cash and plans added ALTO-207 Phase 3", "summary": "Alto Neuroscience (NYSE: ANRO) reported a preliminary estimate of approximately $244.2 million in cash, cash equivalents, and restricted cash as of June 30, 2026. This unaudited figure is subject to change after the completion of accounting procedures. Additionally, the company a", "url": "https://www.stocktitan.net/sec-filings/ANRO/8-k-alto-neuroscience-inc-reports-material-event-1f3655f08ab2.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:15:55", "published_display": "13 Jul 2026 13:15", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock", "summary": "Alto Neuroscience (NYSE: ANRO) announced the pricing of a $100.0 million registered direct offering of 3,776,436 shares of its common stock at $26.48 per share. The company plans to use the proceeds, along with existing cash, to accelerate and expand the clinical development of A", "url": "https://www.businesswire.com/news/home/20260713672035/en/Alto-Neuroscience-Announces-Pricing-of-%24100.0-Million-Underwritten-Registered-Direct-Offering-of-Common-Stock", "source_name": "Business Wire", "published_at": "2026-07-13T11:46:33", "published_display": "13 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc. Stock 12\u2011Month Price Target Cut to $34.8, Implies 33% Upside", "summary": "Analysts have slightly lowered their average 12-month price target for Alto Neuroscience, Inc. (ANRO) stock from $35.11 to $34.80, with a range of $24 to $50 per share. Despite the slight reduction, the updated target still suggests a 33% potential upside based on the July 8 clos", "url": "https://www.tradingview.com/news/tradingview:17e1cb75c43c9:0-alto-neuroscience-inc-stock-12-month-price-target-cut-to-34-8-implies-33-upside/", "source_name": "TradingView", "published_at": "2026-07-09T04:40:53", "published_display": "09 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Alto Neuroscience, Inc. \u2013 NYSE:ANRO", "summary": "This article provides the \"Price to earnings forward\" value for Alto Neuroscience, Inc. (NYSE: ANRO). It indicates that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The core content is a financial metric for ANRO.", "url": "https://www.tradingview.com/symbols/NYSE-ANRO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T03:41:11", "published_display": "04 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience Announces Participation in Upcoming Investor Conferences", "summary": "Alto Neuroscience, Inc. (NYSE: ANRO) announced its participation in two upcoming investor conferences in May and June 2026. The company's management team will present at the Bank of America Securities Healthcare Conference and the Jefferies Global Healthcare Conference, with webc", "url": "https://natlawreview.com/press-releases/alto-neuroscience-announces-participation-upcoming-investor-conferences", "source_name": "The National Law Review", "published_at": "2026-07-03T22:09:37", "published_display": "03 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?", "summary": "Alto Neuroscience, Inc. (ANRO) shows promise for growth following new insights into anhedonia treatment and strategic board appointments. A study published in Nature Medicine highlighted the effectiveness of pramipexole, a dopamine agonist, in reducing anhedonia in patients with ", "url": "https://www.insidermonkey.com/blog/is-alto-neuroscience-inc-anro-stock-positioned-for-growth-with-new-insights-into-anhedonia-treatment-1793957/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-02T20:09:44", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Up and Coming Pharmaceutical Stocks to Buy Now", "summary": "This article identifies Alto Neuroscience, Inc. (NYSE:ANRO) as one of the top up-and-coming pharmaceutical stocks. The company recently highlighted the publication of positive results from an independent study on pramipexole for mood disorders in Nature Medicine, showing signific", "url": "https://www.insidermonkey.com/blog/5-best-up-and-coming-pharmaceutical-stocks-to-buy-now-1792771/3/", "source_name": "Insider Monkey", "published_at": "2026-06-30T18:03:00", "published_display": "30 Jun 2026 18:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index", "summary": "Alto Neuroscience, Inc. (NYSE:ANRO) has been added to the Russell 2000 Index, reflecting its growing presence in the market. The company, a clinical-stage biopharmaceutical firm, focuses on precision psychiatry by using neurobiology and brain biomarkers to develop personalized tr", "url": "https://www.marketscreener.com/news/alto-neuroscience-inc-nyse-anro-added-to-russell-2000-index-ce7f5fdfdc8ff025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T22:10:01", "published_display": "29 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark", "summary": "Alto Neuroscience, Inc. (NYSE: ANRO) has been added to the Russell 2500 Growth Benchmark, reflecting a significant inclusion in key market indices. The company, a clinical-stage biopharmaceutical firm, focuses on personalized psychiatry treatments through its Precision Psychiatry", "url": "https://www.marketscreener.com/news/alto-neuroscience-inc-nyse-anro-added-to-russell-2500-growth-benchmark-ce7f5fdfdd8bf522", "source_name": "marketscreener.com", "published_at": "2026-06-29T20:03:00", "published_display": "29 Jun 2026 20:03", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol", "summary": "Levi & Korsinsky is notifying shareholders of Alto Neuroscience, Inc. (ANRO) about a class action lawsuit with a deadline of September 19, 2025. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness of its product pipeline, ALTO-100, for tre", "url": "https://natlawreview.com/press-releases/levi-korsinsky-notifies-alto-neuroscience-inc-anro-shareholders-class-action", "source_name": "The National Law Review", "published_at": "2026-06-28T20:40:17", "published_display": "28 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Shareholders of Class Action Lawsuit And September 19, 2025 Deadline", "summary": "Levi & Korsinsky has announced a class action lawsuit against Alto Neuroscience, Inc. (ANRO) for shareholders who purchased stock between February 2, 2024, and October 22, 2024. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiv", "url": "https://www.natlawreview.com/press-releases/levi-korsinsky-notifies-alto-neuroscience-inc-anro-shareholders-class-action", "source_name": "The National Law Review", "published_at": "2026-06-28T13:40:23", "published_display": "28 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Alto Neuroscience, Inc. (ANRO) - Contact Levi & Korsinsky Before September 19, 2025", "summary": "Levi & Korsinsky, LLP has issued a securities lawsuit alert for investors who suffered losses in Alto Neuroscience, Inc. (NYSE:ANRO) stock. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness and commercial prospects of its product pipelin", "url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-alto-neuroscience-inc-anro-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-06-27T12:09:22", "published_display": "27 Jun 2026 12:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Alto Neuroscience, Inc. (ANRO) and set a $50.00 price target. This recommendation comes despite the company reporting an increased GAAP net loss of $26.24 million for the quarter ending March 31, compared to $15", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16057/h-c-wainwright-remains-a-buy-on-alto-neuroscience-inc-anro/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:10:15", "published_display": "26 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc. Actuals & Estimates (BOATS:ANRO)", "summary": "This article provides key financial data and analyst estimates for Alto Neuroscience, Inc. (ANRO). It details the company's stock ticker, analyst price forecasts, historical high and low stock prices, and upcoming earnings report dates. Additionally, it covers last quarter's earn", "url": "https://www.tradingview.com/symbols/BOATS-ANRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:22", "published_display": "26 Jun 2026 12:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc. (ANRO) Class Action Lawsuit: Levi & Korsi", "summary": "Levi & Korsinsky LLP is reminding investors of Alto Neuroscience, Inc. (ANRO) about a class action lawsuit stemming from the company's initial public offering around February 2, 2024. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness and", "url": "https://natlawreview.com/press-releases/alto-neuroscience-inc-anro-class-action-lawsuit-levi-korsinsky-reminds", "source_name": "The National Law Review", "published_at": "2026-06-26T11:39:38", "published_display": "26 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE:ANRO) Stock Forecast & Analyst Predictions", "summary": "Alto Neuroscience (NYSE:ANRO) is forecast to see a decline in earnings at 1.9% annually, while revenue is projected to grow by 73.7% per year. The company is actively developing several drug candidates, including ALTO-207 for treatment-resistant depression which is entering Phase", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-anro/alto-neuroscience/future", "source_name": "Simply Wall Street", "published_at": "2026-06-18T04:41:20", "published_display": "18 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNN0I3d0pNR0xEbnk4MG9kRDhPLTN5UG1BakNzRlVvalJUNUU5cmpyTHR1a0FkTUxZVlloMWZ5Q2ZYd2duSEhfS201UEcyMHR1TERtYjRrdDZRaE0wVE5RQkxtaFA5ZVRRM3JRNk1TVnd6d2VTTHBDajZBcEFaTUp0Y194dw?oc=5", "source_name": "Market source", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQaTktSk1KRG01SmRCeHV3b2F6Wi11bkl1SnB6UkQ5T3phdVpMX1NUT3Mtal90NUxWSk5IZ3dZMFhXQV9WMS1sMWJGLU5VTVBQeUR0V0NXTnhveHpGU0RXQkplU3Z2RFJ2ZEFLdWRVM2xTQ1JKaElSM2JtS0NXdUVtakp4VTBCdTNqSlQ3U2oxRzQwY0xnd0d5OENKRmx2Z2ZaWjBDUms0SFhDaUV2VFZFaEx0SmQ5NWN2dTNBNXlZS0VfUWR3bGgwTXQ2YTZSUjlZVXRNc0RVNXlPMEZkVEFOVG1zVi1hMF9LQjJkdHdrY2lUNkQ0UXJGYU1PMVJ0RHc?oc=5", "source_name": "PR Newswire", "published_at": "2025-07-22T07:00:00+00:00", "published_display": "22 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE", "summary": "Alto Neuroscience (NYSE: ANRO) has announced an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, aiming to raise approximately $100 million in gross proceeds. The offering is managed by BofA Securities and Stifel, Nicolaus & Company", "url": "https://www.minichart.com.sg/2026/07/14/alto-neuroscience-announces-3-7-million-underwritten-offering-of-common-stock-on-nyse/", "source_name": "Minichart", "published_at": "2026-07-14T16:12:23", "published_display": "14 Jul 2026 16:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $28", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPcHAwbUxnUEExVVV0TldiYU9MU1VwbTVDcldlSmI4R0ppYnVBMkZCQjdhVlViX25QT3RPUy1iOWh2dkt4TFJxaXp0REhJUDZhLTdLbzZyWUFsSkhlV05zV29qYy1adWh0X0MzOFJxd3d2R3FCUzFhWTBpeVhrMW9nbXpvNUlBMDJPbVZjRl9Yd2ZOMzB2VXRocXdlaVFLcnJLZ0JEQUVpS0RRR2VNRWF1VDZWMXI?oc=5", "source_name": "Moomoo", "published_at": "2026-07-14T11:34:21+00:00", "published_display": "14 Jul 2026 11:34", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE: ANRO) sells 3,776,436 shares at $26.48", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNU3hZdUhJM0x0SENzODgwVmV2WUlnT3F0YWR0ek9KNDJpRGlMSkhFM1NydmotUWZMNkdyM0dKaS1LVVhWUE9tcjV3MWhwM2w1eFpXOVpPV2lOdEdSMk1VUzR4Q2dneUVRZ3luQnZvdkZDOEdOV1hxRl9NampFMVFhOEJpQS1lNUZScGFvMTdaRG9YR2lGT3ZnYUpNV2ttYy10YnFEOUJYa20tbGUtU3kwZWpRLVp0X05CMUp1NTZtckdrYW5Tdnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T10:38:21+00:00", "published_display": "14 Jul 2026 10:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE: ANRO) to raise $93.9M in stock sale", "summary": "Alto Neuroscience (NYSE: ANRO) announced it will raise approximately $93.9 million through an underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share. The company plans to use these net proceeds, along with existing cash, to expand the clin", "url": "https://www.stocktitan.net/sec-filings/ANRO/8-k-alto-neuroscience-inc-reports-material-event-956e138c0ce0.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:13:25", "published_display": "14 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Latham Advises on Alto Neuroscience\u2019s US$100 Million Underwritten Registered Direct Offering of Common Stock", "summary": "Latham & Watkins LLP is advising the underwriters for Alto Neuroscience, Inc.'s underwritten registered direct offering of 3,776,436 shares of common stock. The offering is priced at US$26.48 per share, expecting to generate approximately US$100 million in gross proceeds. The dea", "url": "https://www.lw.com/en/news/2026/07/latham-advises-on-alto-neuroscience-underwritten-registered-direct-offering-of-common-stock", "source_name": "Latham & Watkins LLP", "published_at": "2026-07-13T17:09:54", "published_display": "13 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE: ANRO) estimates $244.2M cash and plans added ALTO-207 Phase 3", "summary": "Alto Neuroscience (NYSE: ANRO) reported a preliminary estimate of approximately $244.2 million in cash, cash equivalents, and restricted cash as of June 30, 2026. This unaudited figure is subject to change after the completion of accounting procedures. Additionally, the company a", "url": "https://www.stocktitan.net/sec-filings/ANRO/8-k-alto-neuroscience-inc-reports-material-event-1f3655f08ab2.html", "source_name": "Stock Titan", "published_at": "2026-07-13T13:15:55", "published_display": "13 Jul 2026 13:15", "sentiment": "positive", "sentiment_pct": 67, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock", "summary": "Alto Neuroscience (NYSE: ANRO) announced the pricing of a $100.0 million registered direct offering of 3,776,436 shares of its common stock at $26.48 per share. The company plans to use the proceeds, along with existing cash, to accelerate and expand the clinical development of A", "url": "https://www.businesswire.com/news/home/20260713672035/en/Alto-Neuroscience-Announces-Pricing-of-%24100.0-Million-Underwritten-Registered-Direct-Offering-of-Common-Stock", "source_name": "Business Wire", "published_at": "2026-07-13T11:46:33", "published_display": "13 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc. Stock 12\u2011Month Price Target Cut to $34.8, Implies 33% Upside", "summary": "Analysts have slightly lowered their average 12-month price target for Alto Neuroscience, Inc. (ANRO) stock from $35.11 to $34.80, with a range of $24 to $50 per share. Despite the slight reduction, the updated target still suggests a 33% potential upside based on the July 8 clos", "url": "https://www.tradingview.com/news/tradingview:17e1cb75c43c9:0-alto-neuroscience-inc-stock-12-month-price-target-cut-to-34-8-implies-33-upside/", "source_name": "TradingView", "published_at": "2026-07-09T04:40:53", "published_display": "09 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Alto Neuroscience, Inc. \u2013 NYSE:ANRO", "summary": "This article provides the \"Price to earnings forward\" value for Alto Neuroscience, Inc. (NYSE: ANRO). It indicates that the data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The core content is a financial metric for ANRO.", "url": "https://www.tradingview.com/symbols/NYSE-ANRO/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T03:41:11", "published_display": "04 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience Announces Participation in Upcoming Investor Conferences", "summary": "Alto Neuroscience, Inc. (NYSE: ANRO) announced its participation in two upcoming investor conferences in May and June 2026. The company's management team will present at the Bank of America Securities Healthcare Conference and the Jefferies Global Healthcare Conference, with webc", "url": "https://natlawreview.com/press-releases/alto-neuroscience-announces-participation-upcoming-investor-conferences", "source_name": "The National Law Review", "published_at": "2026-07-03T22:09:37", "published_display": "03 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?", "summary": "Alto Neuroscience, Inc. (ANRO) shows promise for growth following new insights into anhedonia treatment and strategic board appointments. A study published in Nature Medicine highlighted the effectiveness of pramipexole, a dopamine agonist, in reducing anhedonia in patients with ", "url": "https://www.insidermonkey.com/blog/is-alto-neuroscience-inc-anro-stock-positioned-for-growth-with-new-insights-into-anhedonia-treatment-1793957/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-07-02T20:09:44", "published_display": "02 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Best Up and Coming Pharmaceutical Stocks to Buy Now", "summary": "This article identifies Alto Neuroscience, Inc. (NYSE:ANRO) as one of the top up-and-coming pharmaceutical stocks. The company recently highlighted the publication of positive results from an independent study on pramipexole for mood disorders in Nature Medicine, showing signific", "url": "https://www.insidermonkey.com/blog/5-best-up-and-coming-pharmaceutical-stocks-to-buy-now-1792771/3/", "source_name": "Insider Monkey", "published_at": "2026-06-30T18:03:00", "published_display": "30 Jun 2026 18:03", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index", "summary": "Alto Neuroscience, Inc. (NYSE:ANRO) has been added to the Russell 2000 Index, reflecting its growing presence in the market. The company, a clinical-stage biopharmaceutical firm, focuses on precision psychiatry by using neurobiology and brain biomarkers to develop personalized tr", "url": "https://www.marketscreener.com/news/alto-neuroscience-inc-nyse-anro-added-to-russell-2000-index-ce7f5fdfdc8ff025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T22:10:01", "published_display": "29 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark", "summary": "Alto Neuroscience, Inc. (NYSE: ANRO) has been added to the Russell 2500 Growth Benchmark, reflecting a significant inclusion in key market indices. The company, a clinical-stage biopharmaceutical firm, focuses on personalized psychiatry treatments through its Precision Psychiatry", "url": "https://www.marketscreener.com/news/alto-neuroscience-inc-nyse-anro-added-to-russell-2500-growth-benchmark-ce7f5fdfdd8bf522", "source_name": "marketscreener.com", "published_at": "2026-06-29T20:03:00", "published_display": "29 Jun 2026 20:03", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol", "summary": "Levi & Korsinsky is notifying shareholders of Alto Neuroscience, Inc. (ANRO) about a class action lawsuit with a deadline of September 19, 2025. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness of its product pipeline, ALTO-100, for tre", "url": "https://natlawreview.com/press-releases/levi-korsinsky-notifies-alto-neuroscience-inc-anro-shareholders-class-action", "source_name": "The National Law Review", "published_at": "2026-06-28T20:40:17", "published_display": "28 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Shareholders of Class Action Lawsuit And September 19, 2025 Deadline", "summary": "Levi & Korsinsky has announced a class action lawsuit against Alto Neuroscience, Inc. (ANRO) for shareholders who purchased stock between February 2, 2024, and October 22, 2024. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiv", "url": "https://www.natlawreview.com/press-releases/levi-korsinsky-notifies-alto-neuroscience-inc-anro-shareholders-class-action", "source_name": "The National Law Review", "published_at": "2026-06-28T13:40:23", "published_display": "28 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Securities Lawsuit Alert: Alto Neuroscience, Inc. (ANRO) - Contact Levi & Korsinsky Before September 19, 2025", "summary": "Levi & Korsinsky, LLP has issued a securities lawsuit alert for investors who suffered losses in Alto Neuroscience, Inc. (NYSE:ANRO) stock. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness and commercial prospects of its product pipelin", "url": "https://www.natlawreview.com/press-releases/securities-lawsuit-alert-alto-neuroscience-inc-anro-contact-levi-korsinsky", "source_name": "The National Law Review", "published_at": "2026-06-27T12:09:22", "published_display": "27 Jun 2026 12:09", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)", "summary": "H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating for Alto Neuroscience, Inc. (ANRO) and set a $50.00 price target. This recommendation comes despite the company reporting an increased GAAP net loss of $26.24 million for the quarter ending March 31, compared to $15", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/16057/h-c-wainwright-remains-a-buy-on-alto-neuroscience-inc-anro/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:10:15", "published_display": "26 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc. Actuals & Estimates (BOATS:ANRO)", "summary": "This article provides key financial data and analyst estimates for Alto Neuroscience, Inc. (ANRO). It details the company's stock ticker, analyst price forecasts, historical high and low stock prices, and upcoming earnings report dates. Additionally, it covers last quarter's earn", "url": "https://www.tradingview.com/symbols/BOATS-ANRO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:11:22", "published_display": "26 Jun 2026 12:11", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience, Inc. (ANRO) Class Action Lawsuit: Levi & Korsi", "summary": "Levi & Korsinsky LLP is reminding investors of Alto Neuroscience, Inc. (ANRO) about a class action lawsuit stemming from the company's initial public offering around February 2, 2024. The lawsuit alleges that Alto Neuroscience made false statements regarding the effectiveness and", "url": "https://natlawreview.com/press-releases/alto-neuroscience-inc-anro-class-action-lawsuit-levi-korsinsky-reminds", "source_name": "The National Law Review", "published_at": "2026-06-26T11:39:38", "published_display": "26 Jun 2026 11:39", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alto Neuroscience (NYSE:ANRO) Stock Forecast & Analyst Predictions", "summary": "Alto Neuroscience (NYSE:ANRO) is forecast to see a decline in earnings at 1.9% annually, while revenue is projected to grow by 73.7% per year. The company is actively developing several drug candidates, including ALTO-207 for treatment-resistant depression which is entering Phase", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-anro/alto-neuroscience/future", "source_name": "Simply Wall Street", "published_at": "2026-06-18T04:41:20", "published_display": "18 Jun 2026 04:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Alto Neuroscience, Inc. (ANRO) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNN0I3d0pNR0xEbnk4MG9kRDhPLTN5UG1BakNzRlVvalJUNUU5cmpyTHR1a0FkTUxZVlloMWZ5Q2ZYd2duSEhfS201UEcyMHR1TERtYjRrdDZRaE0wVE5RQkxtaFA5ZVRRM3JRNk1TVnd6d2VTTHBDajZBcEFaTUp0Y194dw?oc=5", "source_name": "Market source", "published_at": "2025-10-23T07:00:00+00:00", "published_display": "23 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxQaTktSk1KRG01SmRCeHV3b2F6Wi11bkl1SnB6UkQ5T3phdVpMX1NUT3Mtal90NUxWSk5IZ3dZMFhXQV9WMS1sMWJGLU5VTVBQeUR0V0NXTnhveHpGU0RXQkplU3Z2RFJ2ZEFLdWRVM2xTQ1JKaElSM2JtS0NXdUVtakp4VTBCdTNqSlQ3U2oxRzQwY0xnd0d5OENKRmx2Z2ZaWjBDUms0SFhDaUV2VFZFaEx0SmQ5NWN2dTNBNXlZS0VfUWR3bGgwTXQ2YTZSUjlZVXRNc0RVNXlPMEZkVEFOVG1zVi1hMF9LQjJkdHdrY2lUNkQ0UXJGYU1PMVJ0RHc?oc=5", "source_name": "PR Newswire", "published_at": "2025-07-22T07:00:00+00:00", "published_display": "22 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 31, "sentiment_summary": {"positive": 14, "negative": 6, "neutral": 11, "score": 55, "total": 31, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 72, "events": [{"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "general", "label": "Market update", "weight": 4.95, "count": 9}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}], "positive_events": 14, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 26.48, "latest_week": "2026-07-10", "one_week_move": 6.9, "four_week_move": 23.3, "twelve_week_move": -4.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.129649, "market_dynamics_buy_signal": false, "relative_strength": 60.632895, "fair_value_gap": 139.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.6667, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.9% over one week, +23.3% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 6}, {"label": "The National Law Review", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "Insider Monkey", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Minichart", "count": 1}, {"label": "Moomoo", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 23}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 12}, {"label": "Market update", "count": 9}, {"label": "Regulatory and legal", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "23", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.9% over one week, +23.3% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Alto Neuroscience Announces $3.7 Million Underwritten Offering of Common Stock on NYSE"}], "updated_at": "2026-07-16T00:50:07.703760+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}